Skip to content

C4 Therapeutics, Inc.

CCCC· NasdaqCore metricsCIK 1662579

Biological products, except diagnostic substances175 peers

Last sale
Nov 6, 2026 · +4.22%
Market cap
$405.11M
131.32M shares
Filings
552
$8.47M
Q3 2026+1.0% FY25 yoy
-$21.84M
Q3 2026N/M FY25 yoy
-$24.60M
Q3 2026N/M FY25 yoy
-$57.59M
Q3 2026derivedN/M FY25 yoy
-$0.16
Q3 2026N/M FY25 yoy
$32.43M
Q3 2026+34.4% FY25 yoy
$405.11M
—
12.6×
1.8×
-19.68%
—

Twelve months to Sep 30, 2026 · derived

Price

$3.09+30.44%+$0.72past year
Nov 6, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$35.95MFY 2025
$45.79M0FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$35,947,000reported
FY 20242024-12-31$35,584,000reported
FY 20232023-12-31$20,756,000reported
FY 20222022-12-31$31,096,000reported
FY 20212021-12-31$45,785,000reported

Capital returns

Dividends and buybacks · FY2019 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—$193.00K$193.00K—97.58M sh+37.5%—
FY2024—$194.00K$194.00K—70.99M sh+3.5%—
FY2023—$110.00K$110.00K—68.60M sh+13.5%—
FY2022—$0.00$0.00—60.47M sh+24.1%—
FY2020—$194.00K$194.00K—43.12M sh+2,922.4%—

Biological products, except diagnostic substances

C4 Therapeutics, Inc. is the 50th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

C4 Therapeutics, Inc. · CIK 1662579 · Engraved from SEC EDGAR